1. Homepagina
  2. Aandelen
  3. Frankrijk
  4. Euronext Paris
  5. Sanofi
  6. Nieuws
  7. Persberichten
    SAN   FR0000120578

SANOFI

(SAN)
  Rapport
Real Time Euronext Paris  -  16:18 01-07-2022
97.10 EUR   +0.79%
13:34Regeneron rondt overname van rechten op kankermedicijn van Sanofi af
MT
30/06Sanofi's geneesmiddelentests voor multiple sclerose, myasthenia gravis gedeeltelijk stopgezet door FDA; inschrijving in VS opgeschort
MT
30/06Sanofi kondigt aan dat de patiënteninschrijving voor Fase III proeven met Tolebrutinib in de V.S. wordt opgeschort
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiële publicatiesSectornieuwsAnalyse MarketScreener
Communiqués de presse de la société SANOFI
30/06SANOFI : Media Update - Form 6-K
PU
30/06MEDIA UPDATE : Patient enrollment of phase III tolebrutinib trials paused in the U.S.
PU
28/06SANOFI : GSK first to report a successful efficacy study against Omicron with COVID-19 Bet..
PU
28/06Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new ..
AQ
24/06Availability of the Q2 2022 Memorandum for modelling purposes
GL
24/06Availability of the Q2 2022 Memorandum for modelling purposes
AQ
24/06PRESS RELEASE : Sanofi-GSK first to report a successful efficacy study against Omicron wit..
GL
22/06MEDIA UPDATE : Survey: Physicians and pharmacists would tell CDC to recommend vaccine like..
PU
14/06Digital growth focus of Sanofi's new Digital Accelerator
AQ
13/06SANOFI : FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6..
PU
13/06Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against var..
AQ
13/06PRESS RELEASE : Sanofi-GSK next-generation COVID-19 booster delivers strong immune respons..
GL
13/06PRESS RELEASE : Sanofi-GSK next-generation COVID-19 booster delivers strong immune respons..
AQ
10/06MEDIA UPDATE : Sanofi, a leader in immune-mediated rare blood disorders, to present latest..
PU
09/06Pfizer's CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position,..
AQ
08/06Sanofi launches 2022 global Employee Stock Purchase Plan for 86,000 people
AQ
08/06Regeneron Pharmaceuticals, Inc. - FDA APPROVES DUPIXENT (DUPILUMAB) AS FIRST BIOLOGIC M..
AQ
08/06Sanofi launches its first Digital Accelerator fueled by new talent and focused on growt..
GL
07/06PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first biologic medicine for children..
GL
07/06PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first biologic medicine for children..
AQ
07/06FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Month..
PR
07/06SANOFI : FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A -..
PU
07/06Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing
PR
07/06Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people
GL
07/06Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people
GL
02/06Sanofi India appoints Preeti Futnani as General Manager, Vaccines
AQ
02/06Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab)
AQ
02/06PRESS RELEASE : Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (ce..
GL
02/06PRESS RELEASE : Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (ce..
AQ
01/06Fda accepts dupixent (dupilumab) for priority review in adults with prurigo nodularis
AQ
01/06PRESS RELEASE : FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemoph..
GL
01/06FDA grants efanesoctocog alfa Breakthrough Therapy designation for haemophilia A
AQ
01/06PRESS RELEASE : FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemoph..
AQ
31/05SANOFI : Update on Cialis® Rx-to-OTC Switch Actual Use Trial - Form 6-K
PU
31/05Fda accepts dupixent for priority review in adults with prurigo nodularis
AQ
31/05FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
AQ
31/05PRESS RELEASE : FDA accepts Dupixent® (dupilumab) for priority review in adults with pruri..
GL
31/05PRESS RELEASE : FDA accepts Dupixent® (dupilumab) for priority review in adults with pruri..
AQ
31/05FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
PR
30/05PRESS RELEASE : Update on Cialis® Rx-to-OTC Switch Actual Use Trial
GL
30/05PRESS RELEASE : Update on Cialis® Rx-to-OTC Switch Actual Use Trial
AQ
26/05Sanofi - European Week Against Cancer 2022 - Interview with Santiago Aguirre, Market Le..
AQ
26/05SANOFI : FDA approves Dupixent® (dupilumab) as first treatment for adults and children age..
PU
20/05PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child..
GL
20/05PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child..
AQ
17/05ASCO - New data from fast-growing innovative Oncology pipeline and portfolio to be pres..
AQ
16/05Sanofi - Sarclisa (isatuximab) combination provides unprecedented median progression fr..
AQ
16/05Sarclisa® (isatuximab) combination provides unprecedented median progression free surv..
AQ
15/05PRESS RELEASE : Sarclisa® (isatuximab) combination provides unprecedented median progressi..
AQ
15/05PRESS RELEASE : Sarclisa® (isatuximab) combination provides unprecedented median progressi..
GL
11/05PRESS RELEASE : New nirsevimab data analyses reinforce efficacy against RSV
GL
11/05PRESS RELEASE : New nirsevimab data analyses reinforce efficacy against RSV
AQ
09/05IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi
AQ
04/05Will The Supreme Court Take The Bait? CVSG Issued And Other Updates In The Amgen v. San..
AQ
04/05FOUNDATION S : Sanofi's new philanthropic spearhead
AQ
04/05PRESS RELEASE : Foundation S: Sanofi's new philanthropic spearhead
GL
03/05Annual General Meeting of May 3, 2022
AQ
03/05PRESS RELEASE : Annual General Meeting of May 3, 2022
GL
03/05PRESS RELEASE : Annual General Meeting of May 3, 2022
AQ
29/04SANOFI : teams up with McLaren Racing to accelerate industrial excellence - Form 6-K
PU
28/04SANOFI : Q1 2022 business EPS(1) up 16.1% at CER driven by higher sales and improving marg..
PU
28/04BioMarin Announces Record Revenues in First Quarter 2022
AQ
28/04SANOFI : Q1 Earnings Snapshot
AQ
28/04INTERIM REPORT Q1/2022 : Our financial targets remain in place
AQ
28/04PRESS RELEASE : Sanofi continues to deliver strong business EPS growth driven by higher sa..
AQ
26/04Sanofi teams up with McLaren Racing to accelerate industrial excellence
AQ
26/04PRESS RELEASE : Sanofi teams up with McLaren Racing to accelerate industrial excellence
GL
21/04MEDIA UPDATE : Rezurock® (belumosudil) patient-reported outcomes correlated with clinical ..
PU
19/04SANOFI : Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocy..
PU
14/04Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopeni..
AQ
14/04PRESS RELEASE : Positive Phase 1/2 study results of rilzabrutinib in people with immune th..
PU
14/04PRESS RELEASE : Positive Phase 1/2 study results of rilzabrutinib in people with immune t..
AQ
12/04Sanofi - AGM 03.05.2022 - Availability of Preparatory Documents
GL
08/04Regeneron - dupixent approved by european commission for children aged 6 to 11 years wi..
AQ
07/04SANOFI : FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years a..
PU
1  2  3  4  5  6  7  8  9  10Volgende
Volgende evenement op SANOFI